MassHealth medical specialty and pharmacy policies
IMPORTANT COVID-19 INFORMATION: During the COVID-19 public health emergency, some of our medical specialty and pharmacy policies may be superseded by the information on our COVID-19 FAQ.
Prior authorization information
Medications obtained through the medical benefit
Most medications covered on the medical benefit require prior authorization through Novologix (NLX). Click here for a list of the medications authorized by Novologix*
Helpful information
- Read our authorization process for off label medical specialty medication requests.
- For new-to-market, request authorization through Novologix (NLX). Reference the new-to-market drug policy below for more information.
- For outside of the MGB ACO network, request authorization through Mass General Brigham Health Plan.
*Please note: This list is not inclusive of all medications that require prior authorization by Mass General Brigham Health Plan. This list is specific to covered medications reviewed by NLX only.
-
How to submit authorizations to NovoLogix
Online: Access the NovoLogix online prior authorization tool through the Provider portal
MassHealth Prior Authorization Form | Standard Prior Authorization Form
Phone: 844-345-2803 | Fax: 844-851-0882Check the top of the criteria document for additional information, including program details, benefit designation, and contact information.
-
How to submit authorizations to Mass General Brigham Health
Providers who are outside of the MGB ACO network can submit requests online through the online authorization submission form.
Medications obtained through the pharmacy benefit
For medications covered on the pharmacy benefit, please submit prior authorizations through CVS Caremark using the information below.
To find out if a medication requires prior authorization or if it is listed on the MassHealth formulary please search the MassHealth Drug List.
-
Specialty medications
Specialty medications are required to be filled through a contracted specialty pharmacy after the first fill. To see if a medication is specialty view the Specialty Pharmacy Drug List.
Phone: 866-814-5506 | Fax: 866-249-6155
MassHealth Prior Authorization Form | Standard Prior Authorization Form
Check the top of the criteria document for additional information, including program details, benefit designation, and contact information.
-
Non-specialty medications
Phone: 877-433-7643 | Fax: 866-255-7569
MassHealth Prior Authorization Form | Standard Prior Authorization Form
Check the top of the criteria document for additional information, including program details, benefit designation, and contact information.
Pharmacy policies
Please note, the following policies are pharmacy benefit drugs that are not aligned with MassHealth. If a policy is not listed below search the MassHealth Drug List for criteria.
Medical specialty and dual benefit drug policies
-
A - E
Aldurazyme (laronidase) - Effective 12/04/2023
Asceniv (immune globulin IV, human-slra)
Bavencio (avelumab) - Effective 12/04/2023
Berinert (c1 esterase inhibitor)
Besponsa (inotuzumab ozogamicin)
Bivigam (immune globulin IV, human)
Blenrep (belantamab mafodotin-blmf)
Cerezyme (imiglucerase) - Effective 12/04/2023
Cinryze (c1 esterase inhibitor)
Cutaquig (immune globulin subcutaneous injection, human-hipp)
Cuvitru (immune globulin subcutaneous injection, human)
Elahere (mirvetuximab soravtansine-gynx)
Elaprase (idursulfase) - Effective 12/04/2023
Elelyso (taliglucerase alfa) - Effective 12/04/2023
-
F - M
Flebogamma (immune globulin IV, human)
Gamastan S/D (immune globulin IM, human)
Gammagard (immune globulin injection, human) (IgA~37μg/mL)
Gammagard S/D (immune globulin IV, human) (IgA<1 μg/mL)
Gammaked (immune globulin injection, human)
Gammaplex (immune globulin IV, human)
Gamunex-C (immune globulin injection, human)
Haegarda (c1 esterase inhibitor)
Herceptin Hylecta (trastuzumab-hyaluronidase-oysk)
Hizentra (immune globulin subcutaneous injection, human)
Hyqvia (immune globulin subcutaneous injection, human/hyaluronidase human recombinant)
Imfinzi (durvalumab) - Effective 12/04/2023
Imjudo (tremelimumab-actl) - Effective 12/04/2023
Imlygic (talimogene laherparepvec)
Jemperli (dostarlimub-gxly) - Effective 12/04/2023
Jevtana (cabazitaxel) - Effective 12/04/2023
Kanuma (sebelipase alfa) - Effective 12/04/2023
Keytruda (pembrolizumab) - Effective 12/04/2023
Lamzede (velmanase alfa-tycv) - Effective 12/04/2023
Libtayo (cemiplimab-rwlc) - Effective 12/04/2023
Lumizyme (alglucosidase alfa) - Effective 12/04/2023
Lupaneta Pack (leuprolide/norethindrone)
Lupron Depot & Lupron Depot - PED (leuprolide)
Marqibo (vincristine liposome)
Mepsevii (vestronidase alfa-vjbk)
Mepsevii (vestronidase alfa-vjbk) - Effective 12/04/2023
-
N - Z
Naglazyme (galsulfase) - Effective 12/04/2023
Nexviazyme (avalglucosidase alfa-ngpt)
Nexviazyme (avalglucosidase alfa-ngpt) - Effective 12/04/2023
Nulibry (fosdenopterin) - Effective 12/04/2023
Octagam (immune globulin IV, human)
Opdivo (nivolumab) - Effective 12/04/2023
Opdualag (nivolumab and relatlimab-rmbw)
Opdualag (nivolumab and relatlimab-rmbw) - Effective 12/04/2023
Palynziq (pegvaliase-pqpz) - Effective 12/04/2023
Panzyga (immune globulin IV, human-ifas)
Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
Poteligeo (mogamulizumab-kpkc)
Privigen (immune globulin IV, human)
Rebyota (fecal microbiota, live-jslm)
Remodulin (treprostinil injection)
Rituxan (rituximab) & Rituxan Hycela (rituximab and hyaluronidase)
Ruconest (c1 esterase inhibitor)
Ryplazim (plasminogen, human-tvmh)
Simponi Aria (golimumab for infusion)
Step Therapy Protocol Exception
Tecentriq (atezolizumab) - Effective 12/04/2023
Trodelvy (sacituzumab govitecan-hziy)
Vyvgart (efgartigimod alfa-fcab)
Vyxeos (daunorubicine/cytarabine)
Xembify (immune globulin subcutaneous injection, human-klhw)
Xenpozyme (olipudase alfa-rpcp)
Yervoy (ipilimumab) - Effective 12/04/2023
Zynlonta (loncastuximab tesirine-lpyl)
Zynyz (retifanlimab-dlwr) - Effective 12/04/2023
